TOME BIOSCIENCES
Tome Biosciences is a biotechnology company that develops programmable gene insertion technology. Using CRISPR, its technologies allow them to insert any genetic sequence of any size at any location into any genome.
TOME BIOSCIENCES
Social Links:
Industry:
Biotechnology Genetics Medical
Founded:
2021-01-01
Address:
Watertown, Massachusetts, United States
Country:
United States
Website Url:
http://www.tome.bio
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Wordpress Plugins
Official Site Inspections
http://www.tome.bio
- Host name: 83.123.215.35.bc.googleusercontent.com
- IP address: 35.215.123.83
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Tome Biosciences"
Tome Biosciences – The programmable genomic integration …
We would like to show you a description here but the site won’t allow us.See details»
8 months after a $213M fundraise, gene editor Tome …
Aug 22, 2024 After raising $213 million in 2023—one of the year’s largest private biotech rounds—Tome Biosciences is making cuts. After raising 8 months after a $213M fundraise, gene editor Tome makes cutsSee details»
Tome Biosciences debuts with $213M and a new way …
Dec 12, 2023 The $213 million comes via Series A and B rounds amassed since 2021. A lengthy list of investors contributed to the rounds, including a16z Bio + Health, Arch Venture Partners, GV and Longwood Fund. Tome is led by Rahul …See details»
Tome Biosciences - Crunchbase Company Profile
Tome Biosciences may be growing as it has recently emerged from stealth mode with significant financing, indicating a strong financial foundation for its operations. The company secured $213 million in financing, which is a …See details»
Tome Biosciences Launches with Over $200 Million in Funding to …
WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration company, has launched to usher in a new era of genomic …See details»
Editor’s pick: Tome Biosciences | Nature Biotechnology
Jun 19, 2024 Tome uses a viral vector to deliver a normal copy of the defective gene and a lipid nanoparticle to deliver the genome editing machinery that inserts the normal gene where it is needed. The ...See details»
Tome Biosciences Raises $213M to Commercialize MIT …
Dec 15, 2023 Earlier this week, Tome raised $213 million in Series A and B funding from investors including Andreessen Horowitz (a16z) Bio + Health, ARCH Venture Partners, GV, Longwood Fund, Polaris Partners ...See details»
Tome Biosciences to lay off nearly entire staff | STAT
Aug 23, 2024 In a layoff notice filed Friday in Massachusetts, the gene-editing startup said it would lay off nearly its entire staff of 130 employees.See details»
Tome Biosciences Launches with Over $200 Million in Funding
Dec 12, 2023 Tome Biosciences, Inc., is the programmable genomic integration (PGI) company. Our technologies allow us to insert any genetic sequence of any size at any location in the …See details»
The Next Chapter in Genome Editing? Tome Emerges …
Dec 19, 2023 Dan Lynch, executive venture partner with GV, chairs Tome’s board, which also includes Jorge Conde, a General Partner on the Bio + Health team at Andreessen Horowitz (a16z); Alan Crane ...See details»
Tome launches CRISPR tool for oversized DNA - Nature
Feb 15, 2024 Tome has shown that its tool can insert sequences of ~36 kb in various dividing and non-dividing cell types. And, unlike other editing tools, it doesn’t rely on repair responses …See details»
Using Programmable Genomic Integration to Make Edits Big and …
Oct 21, 2024 In an interview with CGTLive® held shortly after the close of the conference, John Finn, PhD, the chief scientific officer of Tome Biosciences, spoke about the key implications of …See details»
Tome Biosciences, once a high-flying gene-editing startup, is …
Aug 22, 2024 Buzzy gene-editing startup Tome Biosciences is floundering, just nine months after launching with $213 million in funding, according to several sources with direct …See details»
Tome Biosciences - Funding, Financials, Valuation & Investors
Tome Biosciences is a biotechnology company that develops programmable gene insertion technology. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
Series A - Tome Biosciences - 2023-12-12 - Crunchbase
Dec 12, 2023 Tome Biosciences raised $213000000 on 2023-12-12 in Series A. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. …See details»
Tome Biosciences Launches with Over $200 Million in ... - Bio-IT …
Dec 11, 2023 About Tome. Tome Biosciences, Inc., is the programmable genomic integration (PGI) company. Our technologies allow us to insert any genetic sequence of any size at any …See details»
Genevant secures $114M deal with Tome to develop liver therapy
Jan 16, 2024 Tome launched last month (PDF) with over $200 million to play with, wasting no time in acquiring DNA editing company Replace Therapeutics for $65 million in cash and near …See details»
Tome Biosciences: What Went Wrong and How to Avoid Their Fate
Aug 26, 2024 Tome Biosciences launched in December 2023 with an ambitious goal: to revolutionize gene editing through their innovative Programmable Genomic Integration (PGI) …See details»
Tome Biosciences - Contacts, Employees, Board Members
Organization. Tome Biosciences . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... About. Tome Biosciences has 1 current …See details»
Tom Cruise - Biography, Age, Actor, Married Life
1 day ago Tom Cruise | Biography Tom Cruise is a prominent Hollywood actor known for his roles in the Mission: Impossible franchise and Top Gun. He has been a major figure in the film …See details»